Prediabetes Market
Get a free sample of this report
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
Request Sectional Data
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
Prediabetes Market size was valued at around USD 198.4 million in 2023 and is estimated to reach over USD 360.6 million by 2032 with a CAGR of 6.9%. Prediabetes is a condition characterized by blood sugar levels that are higher than normal but not yet high enough to be classified as type 2 diabetes. It is considered an intermediate stage between normal glucose levels and diabetes. One of the primary catalysts for the market is the rising prevalence of prediabetes worldwide.
Factors such as sedentary lifestyles, unhealthy dietary habits, obesity, and aging populations contribute to the growing prevalence of prediabetes. For instance, in 2021, the Centers for Disease Control and Prevention (CDC) reported that there was a total of 97.6 million adults aged 18 years or older with prediabetes, comprising 38.0% of the adult population in the U.S. Among adults aged 65 years or older, 27.2 million individuals, accounting for 48.8% of this age group, were identified as having prediabetes. Thus, as more people are diagnosed with prediabetes, there is an increasing demand for preventive measures and interventions to manage and potentially reverse this condition.
Pharmaceutical companies are investing in research and development to innovate antidiabetics drug formulations for the management of prediabetes. These innovations include advance pharmaceutical drug delivery which is estimated to reach USD 3.2 trillion by 2032, such as novel drug delivery systems, combination therapies, and medications with improved efficacy and safety profiles. By developing more effective pharmacological interventions for prediabetes, companies aim to address the unmet medical needs of individuals at risk of developing type 2 diabetes and enhance the options available for healthcare providers.
Report Attribute | Details |
---|---|
Base Year: | 2023 |
Prediabetes Market Size in 2023: | USD 198.4 Million |
Forecast Period: | 2024 – 2032 |
Forecast Period 2023 - 2032 CAGR: | 6.9 |
2023 Value Projection: | USD 360.6 Million |
Historical Data for: | 2021 – 2023 |
No of Pages: | 167 |
Tables, Charts & Figures: | 217 |
Segments Covered: | Drug Class, Age Group, Distribution Channel, and Region |
Growth Drivers: |
|
Pitfalls Challenges: |
|
Based on drug class, the market is segmented into biguanides, thiazolidinediones, glucagon-like peptide-1 agonists (GLP-1), sodium-glucose cotransporter 2 inhibitors (SGLT2), dipeptidyl peptidase-4 inhibitors (DPP-4), and other drug classes. The biguanides segment is estimated to account for USD 254.6 million by the end of 2032.
Based on age group, the prediabetes market is segmented into children (12-18 years), adults (18-49), and elderly (50+). The adults (18-49) segment held a substantial revenue of USD 92.7 million in 2023.
Based on distribution channel, the prediabetes market is segmented into wholesalers/distributors, retail chain, online distribution, and other distribution channels. The wholesalers/distributors segment held a substantial revenue of USD 126.8 million in 2023.
In 2023, North America held a significant market share of 40.7% in the prediabetes market and is predicted to witness substantial market growth over the analysis timeline.
The prediabetes industry is competitive in nature, with several large multinationals and small and mid-sized companies competing in the industry. The development and launch of novel advanced products based on different technologies is among a key market strategy. Some of the leading industry players have a notable presence in the market.
Some of the eminent market participants operating in the prediabetes industry include:
Market, By Drug Class
Market, By Age Group
Market, By Distribution Channel
The above information is provided for the following regions and countries:
Prominent prediabetes firms are Abbott Laboratories, AstraZeneca PLC, CH Boehringer Sohn AG & Co KG, Eli Lilly and Company, Glenmark Pharmaceuticals Limited, Johnson & Johnson, Merck & Co., Inc., Novartis AG, Novo Nordisk A/S, Pfizer Inc., Takeda Pharmaceutical Company Limited, among others.
North America prediabetes industry captured 40.7% revenue share in 2023, driven by high prevalence of prediabetes in the region, rising obesity rates, and sedentary lifestyles.
Prediabetes industry size recorded USD 198.4 million in 2023 and will grow at a 6.9% CAGR between 2024 and 2032 owing to rise in obesity rates and sedentary lifestyles, emphasis on preventive healthcare measures and investments in screening programs.
The biguanides segment in the prediabetes industry will register USD 254.6 million by 2032, attributed to the effectiveness and widespread use of biguanides, such as metformin, as a first-line treatment for prediabetes.